Physician profile
Revathi Suppiah
NPI 1760644116
$1,924.84
in general payments reported to CMS, 2019-2025
22 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,143 · 2020: $264 · 2022: $98.47 · 2023: $173 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343 · Education: $75.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.39 |
| Education | $75.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $366.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $288.21 | 2019-2025 | Welireg |
| Galvanize Therapeutics, INC | $145.70 | 2025 | Aliya System |
| Pfizer INC. | $138.45 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $117.84 | 2019-2020 | |
| Genentech USA, INC. | $117.13 | 2019 | |
| Astellas Pharma US INC | $115.41 | 2019 | |
| Sobi, INC | $101.98 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $83.97 | 2022-2023 | Imfinzi |
| Genzyme Corporation | $59.73 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.50 | 2019-2020 | |
| Emd Serono, INC. | $56.48 | 2019 | |
| Celgene Corporation | $38.88 | 2019 | |
| Amgen INC. | $34.06 | 2019 | |
| Lilly USA, LLC | $33.95 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $29.99 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.54 | 2023 | |
| Janssen Biotech, INC. | $24.76 | 2022 | |
| Abbvie INC. | $24.41 | 2025 | |
| Eisai INC. | $23.43 | 2023 | |
| Janssen Pharmaceuticals, INC | $21.48 | 2020 | |
| Seagen INC. | $20.11 | 2023 | Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Revathi Suppiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.